Inotuzumab Ozogamicin (IO)

DRUG2 trials

Sponsors

Gruppo Italiano Malattie EMatologiche dell'Adulto, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Acute Lymphoid LeukemiaPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Phase 2

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Active, not recruitingNCT03610438

Gruppo Italiano Malattie EMatologiche dell'AdultoAcute Lymphoid Leukemia

Start: 2019-10-30End: 2026-10-01Target: 76Updated: 2026-07-16

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

Not yet recruitingNCT07643103

Institute of Hematology & Blood Diseases Hospital, ChinaPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Start: 2026-06-12End: 2030-05-31Target: 32Updated: 2026-06-11

Related Papers

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood2022-11-1511 citations